Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America ; Molecular Imaging Center, Mallinckrodt Institute of Radiology, BRIGHT Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America ; Department of Cancer Systems Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.
Molecular Imaging Center, Mallinckrodt Institute of Radiology, BRIGHT Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.
PLoS One. 2014 Feb 21;9(2):e88855. doi: 10.1371/journal.pone.0088855. eCollection 2014.
Peptide probes for imaging retinal ganglion cell (RGC) apoptosis consist of a cell-penetrating peptide targeting moiety and a fluorophore-quencher pair flanking an effector caspase consensus sequence. Using ex vivo fluorescence imaging, we previously validated the capacity of these probes to identify apoptotic RGCs in cell culture and in an in vivo rat model of N-methyl- D-aspartate (NMDA)-induced neurotoxicity. Herein, using TcapQ488, a new probe designed and synthesized for compatibility with clinically-relevant imaging instruments, and real time imaging of a live rat RGC degeneration model, we fully characterized time- and dose-dependent probe activation, signal-to-noise ratios, and probe safety profiles in vivo. Adult rats received intravitreal injections of four NMDA concentrations followed by varying TcapQ488 doses. Fluorescence fundus imaging was performed sequentially in vivo using a confocal scanning laser ophthalmoscope and individual RGCs displaying activated probe were counted and analyzed. Rats also underwent electroretinography following intravitreal injection of probe. In vivo fluorescence fundus imaging revealed distinct single-cell probe activation as an indicator of RGC apoptosis induced by intravitreal NMDA injection that corresponded to the identical cells observed in retinal flat mounts of the same eye. Peak activation of probe in vivo was detected 12 hours post probe injection. Detectable fluorescent RGCs increased with increasing NMDA concentration; sensitivity of detection generally increased with increasing TcapQ488 dose until saturating at 0.387 nmol. Electroretinography following intravitreal injections of TcapQ488 showed no significant difference compared with control injections. We optimized the signal-to-noise ratio of a caspase-activatable cell penetrating peptide probe for quantitative non-invasive detection of RGC apoptosis in vivo. Full characterization of probe performance in this setting creates an important in vivo imaging standard for functional evaluation of future probe analogues and provides a basis for extending this strategy into glaucoma-specific animal models.
肽探针可用于检测视网膜神经节细胞(RGC)凋亡,由靶向细胞穿透肽的部分和荧光基团-淬灭基团对组成,中间夹有效应半胱天冬酶的共有序列。我们之前通过离体荧光成像技术验证了这些探针在细胞培养和体内 N-甲基-D-天冬氨酸(NMDA)诱导的神经毒性大鼠模型中识别凋亡 RGC 的能力。在此,我们使用了为与临床相关的成像仪器兼容性而设计和合成的新型探针 TcapQ488 和实时成像的活大鼠 RGC 变性模型,全面描述了探针在体内的时间和剂量依赖性激活、信噪比和探针安全性特征。成年大鼠接受玻璃体内注射四种 NMDA 浓度,然后接受不同剂量的 TcapQ488。使用共聚焦扫描激光检眼镜在体内进行荧光眼底成像,对显示激活探针的单个 RGC 进行计数和分析。大鼠在玻璃体内注射探针后还接受了视网膜电图检查。体内荧光眼底成像显示,玻璃体内 NMDA 注射诱导的 RGC 凋亡可作为单个细胞探针激活的明确指标,与同一眼视网膜平铺片中观察到的相同细胞相对应。探针在体内的峰值激活在探针注射后 12 小时检测到。可检测的荧光 RGC 数量随着 NMDA 浓度的增加而增加;检测灵敏度通常随着 TcapQ488 剂量的增加而增加,直到 0.387nmol 时达到饱和。与对照注射相比,玻璃体内注射 TcapQ488 后的视网膜电图没有明显差异。我们优化了一种半胱天冬酶激活的细胞穿透肽探针的信噪比,用于定量非侵入性检测体内 RGC 凋亡。在这种情况下对探针性能进行全面描述,为未来探针类似物的功能评估创建了重要的体内成像标准,并为将该策略扩展到特定于青光眼的动物模型提供了基础。